Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

STAT+: In China, a flood of controversial clinical trials slows to a trickle

Following patient deaths, China restricts investigator-initiated biotech trials, leaving rare disease families and US investors facing an uncertain future.

STAT+: In China, a flood of controversial clinical trials slows to a trickle

We haven't written up this one. STAT News has the full story — the link below goes straight to it.

Read the original at statnews.com →

More in Health & Medicine

More from Thursday 5 November →